Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | GNAI3 | P08754 | 3/20 | 0.32 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.32 |
| ▸ | GNAI1 | P63096 | 3/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 2/20 | 0.30 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL41978 | 0.88 | SIGMAR1 (0.41) | SIGMAR1HRH3 | |
| SCHEMBL42866 | 0.86 | ACHE (0.37) | ALOX15HRH3HTR1A | |
| SCHEMBL666678 | 0.79 | ALOX15 (0.45) | ALOX15HRH3DRD2HTR1AHTR2A | |
| SCHEMBL42184 | 0.79 | GNAI3 (0.43) | SIGMAR1GNAI3GNAO1GNAI1 | |
| SCHEMBL651943 | 0.77 | GNAO1 (0.52) | SIGMAR1GNAI3GNAO1GNAI1 | |
| SCHEMBL12435664 | 0.77 | CXCR4 (0.46) | SIGMAR1HRH3GNAI3GNAO1GNAI1 | |
| SCHEMBL10883021 | 0.77 | SMN1; SMN2 (0.48) | SIGMAR1HRH3HTR2ADRD3 | |
| SCHEMBL1032225 | 0.77 | SMN1; SMN2 (0.48) | SIGMAR1HRH3HTR2ADRD3 | |
| SCHEMBL9433020 | 0.75 | GNAO1 (0.55) | SIGMAR1HRH3GNAI3GNAO1GNAI1 | |
| SCHEMBL10776413 | 0.75 | GNAO1 (0.55) | SIGMAR1HRH3GNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080033165-A1 | [Beta]-Lactamyl Vasopressin V1a Antagonists and Methods of Use | KOPPEL GARY A | 2008-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080033165-A1 | [Beta]-Lactamyl Vasopressin V1a Antagonists and Methods of Use | AVPR2, AVPR1A, AVPR1B | ALOX15 366/4885SIGMAR1 946/4885HRH3 546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.